GT201400007A - Sales de éteres aza bicíclicos de di-arilo y métodos para preparar los mismos o sus precursores - Google Patents

Sales de éteres aza bicíclicos de di-arilo y métodos para preparar los mismos o sus precursores

Info

Publication number
GT201400007A
GT201400007A GT201400007A GT201400007A GT201400007A GT 201400007 A GT201400007 A GT 201400007A GT 201400007 A GT201400007 A GT 201400007A GT 201400007 A GT201400007 A GT 201400007A GT 201400007 A GT201400007 A GT 201400007A
Authority
GT
Guatemala
Prior art keywords
precursors
methods
arilo
bicyclic
dies
Prior art date
Application number
GT201400007A
Other languages
English (en)
Inventor
Marterer Wolfgang
Prashad Mahavir
Villhauer Edwin Bernard
Waykole Liladhar Murlidhar
Vivelo James Anthony
Sutter Bertrand
Bianchi Jean-Claude
Wu Raeann
Har Denis
Piotr H Karpinski
Pignone Massimo
Stingelin Doris
Buerger Eckart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45478332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201400007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201400007A publication Critical patent/GT201400007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON SALES DE (R)-3-(6-(4-METILFENIL)-PIRIDIN-3-ILOXI)-1-AZA-BICICLO [2.2.2] OCTANO, CON MÉTODOS PARA LA PREPARACIÓN DE LAS MISMAS O LAS DE SUS PRECURSORES, CON COMPOSICIONES FARMACÉUTICAS QUE LAS COMPRENDAN, Y A SU USO COMO MEDICAMENTOS.
GT201400007A 2011-07-15 2014-01-15 Sales de éteres aza bicíclicos de di-arilo y métodos para preparar los mismos o sus precursores GT201400007A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161508147P 2011-07-15 2011-07-15

Publications (1)

Publication Number Publication Date
GT201400007A true GT201400007A (es) 2015-02-19

Family

ID=45478332

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400007A GT201400007A (es) 2011-07-15 2014-01-15 Sales de éteres aza bicíclicos de di-arilo y métodos para preparar los mismos o sus precursores

Country Status (27)

Country Link
US (3) US9365565B2 (es)
EP (2) EP2731946B1 (es)
JP (2) JP6263469B2 (es)
KR (3) KR101846770B1 (es)
CN (2) CN107602552A (es)
AR (1) AR087164A1 (es)
AU (1) AU2012285943B2 (es)
BR (1) BR112014000907A2 (es)
CA (1) CA2841546C (es)
CL (1) CL2014000119A1 (es)
CO (1) CO6852078A2 (es)
EA (1) EA025477B1 (es)
ES (1) ES2611950T3 (es)
GT (1) GT201400007A (es)
HK (2) HK1194069A1 (es)
HU (1) HUE031256T2 (es)
IL (2) IL230447A (es)
JO (1) JO3249B1 (es)
MA (1) MA35263B1 (es)
MX (2) MX359856B (es)
MY (1) MY173454A (es)
PE (1) PE20141939A1 (es)
SI (1) SI2731946T1 (es)
TN (1) TN2013000530A1 (es)
TW (1) TWI589576B (es)
UA (1) UA113409C2 (es)
WO (2) WO2013010679A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013010679A1 (en) * 2011-07-15 2013-01-24 Novartis Ag Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors
EP3251673A1 (en) 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
CN103601748B (zh) * 2013-10-17 2016-11-02 上海交通大学 羟烷基化杂环硼酸酯及其制备方法、用途
US11433057B2 (en) * 2016-05-20 2022-09-06 Vanda Pharmaceuticals Inc. Method for improving or enhancing cognition
JP2020510027A (ja) * 2017-03-08 2020-04-02 アリアド ファーマシューティカルズ，インコーポレーテッド ５−クロロ−ｎ４−［２−（ジメチルホスホリル）フェニル］−ｎ２−｛２−メトキシ−４−［４−（４−メチルピペラジン−１−イル）ピペリジン−１−イル］フェニル｝ピリミジン−２，４−ジアミンを含む医薬製剤
WO2019084459A1 (en) 2017-10-26 2019-05-02 Xynomic Pharmaceuticals, Inc. CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR
EP3981768A4 (en) 2019-06-06 2023-07-12 Genfleet Therapeutics (Shanghai) Inc. POLYMORPH OF CDK9 INHIBITOR AND METHOD OF MANUFACTURE OF POLYMORPH AND USE THEREOF
KR20230112622A (ko) 2020-11-25 2023-07-27 반다 파마슈티칼즈, 인코퍼레이티드. 알파-7 니코틴성 아세틸콜린 수용체 작용제를 사용한 대중 발표 불안증의 치료

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605652A (en) 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
US4863919A (en) 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
UY26942A1 (es) * 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6951880B2 (en) 2002-05-16 2005-10-04 Genelabs Technologies, Inc. Aryl and heteroaryl compounds as antibacterial and antifungal agents
SE0201544D0 (sv) 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
WO2006065233A1 (en) 2004-12-10 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
GB0415746D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
FR2884516B1 (fr) 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
AP2009005047A0 (en) 2007-05-10 2009-12-31 Pfizer Ltd Azetidine derivatives and their use as prostaglandin E2 antagonists
US8349858B2 (en) * 2007-06-21 2013-01-08 Merck Sharp & Dohme Polycyclic guanine derivatives and use thereof
US20090285774A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CA2761858A1 (en) 2009-05-15 2010-11-18 Novartis Ag 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or cyp11b1
AR076707A1 (es) 2009-05-28 2011-06-29 Novartis Ag Derivados amino-propionicos sustituidos como inhibidores de neprilisina
EP2959902A1 (en) * 2009-07-23 2015-12-30 Novartis AG Use of azabicycloalkyl derivatives for the treatment or prevention of ataxia
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
BR112012009292A2 (pt) 2009-10-21 2017-06-06 Glaxo Group Ltd processo para preparação do composto, sal de potássio, solvato de acetona, forma cristalina, e, composto
WO2013010679A1 (en) * 2011-07-15 2013-01-24 Novartis Ag Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors
CA2894384C (en) * 2012-12-11 2018-03-06 Novartis Ag Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
US20150313884A1 (en) * 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists

Also Published As

Publication number Publication date
CA2841546A1 (en) 2013-01-24
BR112014000907A2 (pt) 2017-06-13
TWI589576B (zh) 2017-07-01
AU2012285943A1 (en) 2014-01-23
AU2012285943B2 (en) 2016-03-17
US20160145253A1 (en) 2016-05-26
US20140220125A1 (en) 2014-08-07
UA113409C2 (xx) 2017-01-25
WO2013010916A1 (en) 2013-01-24
ES2611950T3 (es) 2017-05-11
CA2841546C (en) 2020-01-14
EP2731946B1 (en) 2016-09-14
IL230447A (en) 2017-02-28
US9802931B2 (en) 2017-10-31
MX2014000619A (es) 2014-02-27
MY173454A (en) 2020-01-26
WO2013010679A1 (en) 2013-01-24
TN2013000530A1 (en) 2015-03-30
CN103717596A (zh) 2014-04-09
JP6355676B2 (ja) 2018-07-11
EP3075732B1 (en) 2018-09-12
AR087164A1 (es) 2014-02-26
US10421755B2 (en) 2019-09-24
KR20140034309A (ko) 2014-03-19
JP6263469B2 (ja) 2018-01-17
JP2014520824A (ja) 2014-08-25
CL2014000119A1 (es) 2014-07-25
EP3075732A2 (en) 2016-10-05
EA201490283A1 (ru) 2014-06-30
MA35263B1 (fr) 2014-07-03
IL230447A0 (en) 2014-03-31
JO3249B1 (ar) 2018-09-16
JP2016185963A (ja) 2016-10-27
MX359856B (es) 2018-10-12
US20180009801A1 (en) 2018-01-11
KR20180037310A (ko) 2018-04-11
NZ619574A (en) 2015-12-24
CO6852078A2 (es) 2014-01-30
MX348306B (es) 2017-06-06
HUE031256T2 (en) 2017-06-28
IL250353A0 (en) 2017-03-30
CN103717596B (zh) 2017-11-21
SI2731946T1 (sl) 2017-04-26
CN107602552A (zh) 2018-01-19
EP3075732A3 (en) 2017-01-04
PE20141939A1 (es) 2014-12-05
TW201302740A (zh) 2013-01-16
HK1194069A1 (zh) 2014-10-10
KR20170002699A (ko) 2017-01-06
EA025477B1 (ru) 2016-12-30
US9365565B2 (en) 2016-06-14
HK1249505A1 (zh) 2018-11-02
EP2731946A1 (en) 2014-05-21
KR101846770B1 (ko) 2018-04-09

Similar Documents

Publication Publication Date Title
GT201400007A (es) Sales de éteres aza bicíclicos de di-arilo y métodos para preparar los mismos o sus precursores
GT201400196A (es) Compuestos de heterociclilo
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2015000408A1 (es) Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer.
ECSP14013215A (es) Compuestos novedosos
CL2015002567A1 (es) Compuestos y sus usos para modular la hemoglobina
CL2016001895A1 (es) Compuestos
CR20150370A (es) Compuestos antivirales
CR20150228A (es) Inhibidores de la tirosina-quinasa de bruton
UY35467A (es) Compuestos orgánicos
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CU20140089A7 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
ECSP16074478A (es) Compuestos novedosos
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
DOP2016000047A (es) Compuestos y composiciones como inhibidores de la mek
CR20150390A (es) Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2)
CR20130602A (es) Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos